KR910019991A - 시클로덱스트린 복합체 - Google Patents

시클로덱스트린 복합체 Download PDF

Info

Publication number
KR910019991A
KR910019991A KR1019910008574A KR910008574A KR910019991A KR 910019991 A KR910019991 A KR 910019991A KR 1019910008574 A KR1019910008574 A KR 1019910008574A KR 910008574 A KR910008574 A KR 910008574A KR 910019991 A KR910019991 A KR 910019991A
Authority
KR
South Korea
Prior art keywords
group
complex
optionally substituted
optionally
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019910008574A
Other languages
English (en)
Korean (ko)
Inventor
시게루 가메이
히로아끼 오까다
가쓰이찌 스도
쇼지 기시모또
Original Assignee
우메모또 요시마사
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우메모또 요시마사, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 우메모또 요시마사
Publication of KR910019991A publication Critical patent/KR910019991A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
KR1019910008574A 1990-05-25 1991-05-25 시클로덱스트린 복합체 Ceased KR910019991A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP13634390 1990-05-25
JP90-136343 1990-05-25
JP1533391 1991-02-06
JP91-015333 1991-02-06

Publications (1)

Publication Number Publication Date
KR910019991A true KR910019991A (ko) 1991-12-19

Family

ID=26351444

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910008574A Ceased KR910019991A (ko) 1990-05-25 1991-05-25 시클로덱스트린 복합체

Country Status (7)

Country Link
US (1) US5196406A (enExample)
EP (1) EP0461427B1 (enExample)
KR (1) KR910019991A (enExample)
AT (1) ATE148993T1 (enExample)
CA (1) CA2043253C (enExample)
DE (1) DE69124715T2 (enExample)
TW (1) TW282399B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196426T1 (de) * 1991-06-21 2000-10-15 Takeda Chemical Industries Ltd Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate
JP3122203B2 (ja) * 1991-11-13 2001-01-09 塩水港精糖株式会社 新規ヘテロ分岐シクロデキストリンおよびその製造方法
EP0555693B1 (en) * 1992-01-30 2001-09-05 Takeda Chemical Industries, Ltd. Method of producing highly watersoluble cyclodextrin complex
EP0602586B1 (en) * 1992-12-16 1997-06-04 Takeda Chemical Industries, Ltd. Stable pharmaceutical composition of fumagillol derivatives
ATE177632T1 (de) * 1993-09-24 1999-04-15 Takeda Chemical Industries Ltd Antineoplastische pharmazeutische zusammensetzung enthaltend ein fumagillolderivat und einen platinkomplex
US5710148A (en) * 1995-03-06 1998-01-20 Senju Pharmaceuticals Co., Ltd. Corneal opacification inhibitory composition
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7087768B2 (en) 2001-09-27 2006-08-08 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
KR100455900B1 (ko) * 2001-09-27 2004-11-12 주식회사 아이디알 새로운 푸마질롤 유도체 및 그의 제조방법
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
CA2731020A1 (en) 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
CA2786603C (en) 2010-01-08 2018-02-20 James E. Vath Fumagillol type compounds and methods of making and using same
KR20130043207A (ko) 2010-07-22 2013-04-29 자프겐 인크. 트리시클릭 화합물 및 이의 제조 및 사용 방법
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
CA2819251A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
JP5876513B2 (ja) 2011-03-08 2016-03-02 ザフゲン，インコーポレイテッド オキサスピロ［２．５］オクタン誘導体および類似体
FR2973376B1 (fr) * 2011-03-28 2013-05-10 Atlanthera Derives utiles dans le traitement ou la prevention de tumeurs osseuses
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
EP2804856B1 (en) 2012-01-18 2017-03-15 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
EP2847176A1 (en) 2012-05-07 2015-03-18 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
CA2873574A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
CN104918615B (zh) 2012-11-05 2018-10-12 扎夫根股份有限公司 治疗肝病的方法
AU2014236528A1 (en) 2013-03-14 2015-09-24 Zafgen, Inc. Methods of treating renal disease and other disorders
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3260714A (en) * 1964-05-14 1966-07-12 Upjohn Co Quaternary ammonium salts of lincomycin
US3418414A (en) * 1966-08-31 1968-12-24 Upjohn Co Trimethylsilyl ethers of lincomycin and its compounds
US3448097A (en) * 1967-04-25 1969-06-03 Upjohn Co Lincomycin complexes and process for preparing the same
US3856943A (en) * 1971-06-23 1974-12-24 Upjohn Co Compositions and process
US4278789A (en) * 1979-11-23 1981-07-14 The Upjohn Company Lincomycin compounds
US4310660A (en) * 1980-05-19 1982-01-12 The Upjohn Company Lincomycin compounds
US4383109A (en) * 1981-04-20 1983-05-10 The Upjohn Company Lincomycin nucleotides
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4568741A (en) * 1984-05-15 1986-02-04 The Upjohn Company Synthesis of 7-halo-7-deoxylincomycins
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
YU45837B (sh) * 1988-01-18 1992-07-20 LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom
CA1333363C (en) * 1988-01-19 1994-12-06 Judah Folkman Angiogenesis inhibitor comprising fumagillin
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
CN1038304C (zh) * 1988-01-19 1998-05-13 摩塞斯·朱旦·福克迈 生长抑制组合物的制备方法
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US4954496A (en) * 1988-08-12 1990-09-04 Fujisawa Pharmaceutical Company, Ltd. Cyclohexane derivatives and pharmaceutical compositions
EP0359036B1 (en) * 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
ATE106726T1 (de) * 1988-09-01 1994-06-15 Takeda Chemical Industries Ltd Angiogenese hemmendes mittel.
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof

Also Published As

Publication number Publication date
DE69124715D1 (de) 1997-03-27
DE69124715T2 (de) 1997-06-05
US5196406A (en) 1993-03-23
CA2043253A1 (en) 1991-11-26
ATE148993T1 (de) 1997-03-15
TW282399B (enExample) 1996-08-01
EP0461427A2 (en) 1991-12-18
EP0461427A3 (en) 1992-01-08
CA2043253C (en) 2002-10-15
EP0461427B1 (en) 1997-02-19

Similar Documents

Publication Publication Date Title
KR910019991A (ko) 시클로덱스트린 복합체
CN1219517C (zh) RAS－法呢基转移酶抑制剂和磺基丁基醚－7－β－环糊精或2－羟丙基－β－环糊精的复合物及方法
KR910016773A (ko) 시클로덱스트린 유도체의 폴리술페이트 및 이의 제조방법
KR900004333A (ko) 맥관 형성 억제제
KR960004344A (ko) 6원 질소 함유 헤테로아릴-옥사졸리디논
KR900004722A (ko) 푸마길롤 유도체
KR950000693A (ko) 프로펜산 유도체
KR920018026A (ko) 아미노피리딘 화합물
KR850002970A (ko) 시클로헥세놀 유도체의 제조방법
KR920701162A (ko) 퀴놀린 유도체, 당해 유도체를 함유하는 항궤양제 및 당해 유도체의 제조방법
KR910016697A (ko) 테트라히드로피리딘 유도체
KR920002741A (ko) 디케토피롤로피롤을 기재로 하는 전기 발색 조성물
ES2186186T3 (es) Derivados ariloxianilina.
DE69828516D1 (de) (hetero)aryl-sulfonamid derivate, deren herstellung und deren verwenddung als faktor xa inhibitoren
KR880009935A (ko) 피리딘-2,4-및 -2,5-디카복실산 유도체, 이의 제조방법, 이의 용도, 및 이들 화합물을 기본으로 약제
KR840007406A (ko) 중추 신경계에 활성을 나타내는 복소환 화합물의 제조방법
KR880002828A (ko) 디하이드로피리딘 유도체 및 이것의 약학적 조성말
DE69023939D1 (de) Förderung der Osteogenese durch Verwendung von Vitamin D-Derivaten.
Darwish et al. The Racemization of Sulfonium Salts. III. The Racemization of Arylsulfonium Salts
ES417459A1 (es) Procedimiento para la preparacion de bencenosulfonilureas.
FI915570A0 (fi) Inklusionskomplex av 3 -morfolinosydnonimin eller dess salter eller dess tautomera isomerer, foerfarande foer deras framstaellning och farmaceutiska kompositioner innehaollande desamma.
KR910007878A (ko) 디히드로피리딘 유도체 및 의약 조성물
KR880011140A (ko) 벤조디옥솔 유도체
KR950704252A (ko) N-치환 이미다졸 유도체
KR860008148A (ko) 헤테로 사이클릭 아미드 유도체의 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000